News | June 10, 2022

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) June 10, 2022 at 7:00 AM EDT All patients treated with bezuclastinib achieved ≥50% reduction in...

News | April 13, 2022

GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia Momelotinib complements...

News | February 16, 2022

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies   Drug discovery approach uncovers novel biology for treatments that can target multiple diseases with a single therapy. Star...

News | February 16, 2022

Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer   Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion of...

News | March 29, 2022

PASSAGE BIO ANNOUNCES PUBLICATION OF PRECLINICAL DATA THAT SUPPORT ONGOING CLINICAL STUDY OF PBKR03 IN KRABBE DISEASE Preclinical studies conducted with University of Pennsylvania’s Gene Therapy Program demonstrate biologic effects of vector-optimized gene therapy...

News | March 15, 2022

PASSAGE BIO PROVIDES UPDATE ON STRATEGIC PRIORITIES AND EXTENDS CASH RUNWAY Company to reduce workforce and prioritize research and development programs to reduce operating expenses Continued focus on execution of three ongoing clinical trials for GM1 gangliosidosis,...